Effects of Canagliflozin Versus Finerenone on Cardiorenal Outcomes: Exploratory Post-Hoc Analyses From FIDELIO-DKD Compared to Reported CREDENCE Results

Nephrol Dial Transplant 2021;gfab336 doi: 10.1093/ndt/gfab366

The risk of cardiovascular events and chronic kidney disease progression is increased in patients with chronic kidney disease and type 2 diabetes. This analysis identifies the cardiorenal benefits of Fidelio-DKD and CREDENCE.


LinkedIn